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Abstract Apolipoprotein E2 (apoE2)-associated hyperlip-
idemia is characterized by a disturbed clearance of apoE2-
enriched VLDL remnants. Because excess apoE2 inhibits
LPL-mediated triglyceride (TG) hydrolysis in vitro, we in-
vestigated whether direct or indirect stimulation of LPL
activity in vivo reduces the apoE2-associated hypertriglyc-
eridemia. Here, we studied the role of LPL and two potent
modifiers, the LPL inhibitor apoC-III and the LPL activator
apoA-V, in APOE2-knockin (APOE2) mice. Injection of
heparin in APOE2 mice reduced plasma TG by 53% and
plasma total cholesterol (TC) by 18%. Adenovirus-mediated
overexpression of LPL reduced plasma TG by 85% and TC
by 40%. Both experiments indicate that the TG in apoE2-
enriched particles is a suitable substrate for LPL. Indirect
activation of LPL activity via deletion of Apoc3 in APOE2
mice did not affect plasma TG levels, whereas overexpres-
sion of Apoa5 in APOE2 mice did reduce plasma TG by 81%
and plasma TC by 41%. In conclusion, the hypertriglyc-
eridemia in APOE2 mice can be ameliorated by the direct
activation of LPL activity. Indirect activation of LPL via over-
expression of apoA-V does, whereas deletion of apoC-III
does not, affect the plasma TGs in APOE2 mice. These
data indicate that changes in apoA-V levels have a dominant
effect over changes in apoC-III levels in the improvement
of APOE2-associated hypertriglyceridemia.—Gerritsen, G.,
C. C. van der Hoogt, F. G. Schaap, P. J. Voshol, K. E. Kypreos,
N. Maeda, A. K. Groen, L. M. Havekes, P. C. N. Rensen, and
K. W. van Dijk. ApoE2-associated hypertriglyceridemia is
ameliorated by increased levels of apoA-V but unaffected
by apoC-III deficiency. J. Lipid Res. 2008. 49: 1048–1055.
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Apolipoprotein E2 (apoE2)-associated hyperlipidemia
is characterized by increased plasma levels of chylo-
micron and VLDL remnants and is associated with xan-
thomatosis and premature atherosclerosis (1). ApoE2 has
a single amino acid substitution (arginine158Ycysteine)
compared with the common apoE3 variant, resulting in a
low binding affinity for the LDL receptor (2, 3). In vivo,
this is associated with impaired hepatic clearance of VLDL
and chylomicron remnant particles (4), resulting in in-
creased plasma triglyceride (TG) and total cholesterol (TC)
levels. Simultaneously, apoE2 accumulates in plasma,
leading to an increase in apoE-mediated inhibition of
LPL-mediated TG hydrolysis (5). It has been postulated
that both impaired remnant clearance and impaired rem-
nant generation via lipolysis contribute to the hyperlipid-
emia associated with apoE2 (5).
We and others have found that VLDL obtained from
hyperlipidemic patients homozygous for APOE2 is a rel-
atively poor substrate for LPL-mediated lipolysis (6). Two
potent modifiers of LPL activity have been described,
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apoA-V and apoC-III, that are encoded in the same gene
cluster on chromosome 11 (7). In vitro and in vivo mouse
studies indicate that apoA-V stimulates LPL-mediated TG
hydrolysis and that apoC-III inhibits this process (8–12).
Overexpression of apoA-V in mice reduces plasma TG
levels via the stimulation of LPL activity (13), and over-
expression of apoC-III results in increased plasma TG levels
via the inhibition of LPL (14). Studies in Apoc3-knockout
mice show accelerated LPL-mediated TG hydrolysis (15,
16). Deficiency in apoA-V in both mice and humans is
associated with hypertriglyceridemia (17–19).
In the present study, we investigated the role of LPL-
mediated TG hydrolysis in apoE2-associated hyper-
lipidemia in vivo. A direct increase of active LPL in the
circulation of APOE2-knockin (APOE2) mice via heparin
injection and via adenovirus-mediated gene transfer of
LPL reduced both TG and TC levels. Indirect stimulation
of the LPL activity via the deletion of endogenous Apoc3
did not affect the plasma TG levels, whereas indirect
stimulation via adenovirus-mediated overexpression of
Apoa5 resulted in decreased plasma TG and TC levels.
Thus, stimulation of LPL activity via apoA-V overexpression
or apoC-III deficiency occurs via different mechanisms.
METHODS
Adenoviral constructs
The adenoviral vectors expressing enzymatically active LPL
(AdLPL) and inactive LPL (AdLPL-inactive) were kindly pro-
vided by Dr. S. Santamarina-Fojo (20). The generation of the
adenoviral vectors expressing apoA-V (AdApoa5), the control
empty vector (AdEmpty), and b-galactosidase (AdlacZ) has been
described (8, 13). Expansion, purification, and titration of the
adenoviral vectors were performed as described previously (21).
Before in vivo administration, the adenoviral vectors were di-
luted to a dose of 5 3 108 plaque-forming units (pfu) in 200 ml of
sterile PBS.
Mouse models
APOE2-knockin mice, carrying the human APOE2 gene in
place of the mouse Apoe gene, have been described (22). These
mice were backcrossed eight times with C57BL/6 mice to achieve
a more homogenous genetic background and subsequently in-
tercrossed to obtain homozygous APOE2 mice. Apoc32/2 mice
were obtained from Jackson Laboratories (Bar Harbor, ME) and
intercrossed with APOE2 mice to obtain APOE2, APOE2.Apoc31/2,
and APOE2.Apoc32/2 mice. The mice were fed a regular mouse
diet (SRM-A; Hope Farms, Woerden, The Netherlands) and
given free access to food and water. At least 5 days before ade-
novirus injection, mice were transferred to filter-top cages in
designated rooms. All animal experimentation protocols were
approved by the Committee on Animal Experimentation of the
Leiden University Medical Center.
Adenovirus-mediated gene transfer in mice
Male APOE2 mice at 13–18 weeks of age were selected for
injection with AdLPL or AdLPL-inactive. A dose of 5 3 108 pfu
adenovirus was injected into the tail vein. Before and 5 days after
the administration of adenovirus expressing active LPL or in-
active LPL, mice were fasted for 4 h and a blood sample for the
determination of lipids was collected by tail bleeding, using
diethyl-p-nitrophenyl phosphate (paraoxon; Sigma)-coated hep-
arinized capillary tubes (Hawksley, Sussex, England).
Female APOE2 mice at 13–18 weeks of age were injected
with a dose of 5 3 108 pfu AdApoa5 or AdEmpty. Three hours
before this virus injection, the mice were injected with 5 3
108 pfu AdlacZ to saturate the uptake of viral particles by he-
patic Kupffer cells (23). Before and 4 days after virus injection,
mice were fasted for 4 h and a blood sample for the determi-
nation of lipids was collected in paraoxon-coated capillaries by
tail bleeding.
Lipid determinations
Plasma was isolated from blood samples obtained from the mice
by centrifugation. TG and TC levels were measured enzymatically
(Sigma). Human apoE levels were measured by sandwich ELISA
as described previously (24). The circulating human apoE level
in homozygous APOE2-carrying mice was 3.1 6 0.9 mg/dl.
Lipoproteins were separated using fast-protein liquid chro-
matography (FPLC). Plasma pools obtained from the various
groups of mice were diluted five times using PBS. A volume of
50 ml was injected onto a Superose 6 column (3.2 3 30 mm,
AKTA system; Pharmacia, Uppsala, Sweden) to separate lipo-
Fig. 1. Plasma lipid levels of apolipoprotein E2 (APOE2) mice
after heparin treatment. Fasted APOE2 mice were injected with
heparin. Before (time 0) and 10, 30, 60, and 120 min after injec-
tion, plasma samples were obtained and assayed for triglyceride
(TG; A) and cholesterol (B). The values are represented as per-
centages of preinjection levels and are means 6 SD for n 5 4 mice
per group. WT, wild type.
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protein fractions. Elution fractions of 50 ml were collected and
assayed enzymatically for TG and TC levels as described above.
Heparin treatment
Heparin (or vehicle) was administered to APOE2 mice after a
period of 4 h of fasting via intravenous injection of a dose of
0.5 U/g body weight. Blood samples of ?30 ml were drawn via the
tail vein at 0, 10, 30, 60, and 120 min after heparin injection using
paraoxon-coated capillaries. Plasma TG levels were measured
enzymatically as described above.
Fat load
The fat load response was determined in male APOE2,
APOE2.Apoc31/2, and APOE2.Apoc32/2 mice aged 13–20 weeks.
The mice were fasted overnight and given an intragastric olive oil
load (Carbonell, Cordoba, Spain) of 400 ml. Before the olive oil
load and 3 h after the load, a blood sample was drawn via the tail
vein for plasma TG determination. The circulating TG levels
were corrected for the TG level before the fat load.
Statistical analysis
Data were analyzed using the nonparametric Mann-Whitney
test. P , 0.05 was regarded as statistically significant.
RESULTS
Effect of increased plasma LPL level on lipid levels in
APOE2 mice
Intravenous injection of heparin results in an increase
of active LPL in the circulation. Stimulation of LPL activity
in APOE2 mice via injection of heparin (0.5 U/g body
weight) reduced the hyperlipidemia in a time-dependent
manner (Fig. 1). The maximum reduction was observed
at 60 min after injection. At this time point, the plasma
TG levels decreased by 53% (Fig. 1A) and the TC levels
decreased by 18% (Fig. 1B). This effect is similar to the
effect of heparin as observed in wild-type mice (Fig. 1).
APOE2 mice were injected with adenovirus expressing
enzymatically active and inactive LPL to further investigate
the suitability of apoE2-containing particles as substrate
for LPL (Fig. 2). At day 5 after injection of 5 3 108 pfu
AdLPL-inactive, APOE2 mice exhibited a 129% increase in
plasma TG levels (Fig. 2A), whereas TC levels were hardly
affected (112.5%) (Fig. 2B). The increase in plasma TG
after AdLPL-inactive administration may be a nonspecific
virus-mediated effect but may also result from the op-
sonization of lipoprotein with inactive protein, thereby
Fig. 2. Plasma lipid levels of APOE2 mice injected with adenoviral
vectors expressing enzymatically active LPL (AdLPL) and inactive
LPL (AdLPL-inactive). APOE2 mice were injected with 5 3 108
plaque-forming units (pfu) AdLPL-inactive or AdLPL. Before
(open bars) and at day 5 after adenovirus injection (closed bars),
fasted plasma samples were assayed for TG (A) and cholesterol (B).
Values are represented as means 6 SD for n 5 3 mice per group.
Fig. 3. Lipoprotein profiles of APOE2 mice injected with AdLPL-
inactive and AdLPL. Pooled plasma samples of APOE2 mice
injected with 5 3 108 pfu AdMock, AdLPL-inactive, and AdLPL
(n 5 3 per group) were subjected to fast-protein liquid chro-
matography (FPLC), and the elution fractions were assayed for TG
(A) and cholesterol (B). IDL, intermediate density lipoprotein.
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preventing the interaction with active LPL at the endo-
thelial surface. In contrast, at day 5 after injection of 5 3
108 pfu AdLPL, APOE2 mice exhibited an 85% decrease in
plasma TG levels (Fig. 2A) and a 40% decrease in TC levels
(Fig. 2B). The lipoprotein distribution as determined by
FPLC showed a decrease in VLDL-TG and VLDL-TC to
wild-type levels after injection of AdLPL, indicating an ac-
celerated conversion of apoE2-containing VLDL particles
by overexpression of LPL (Fig. 3).
Effect of apoC-III deficiency on lipid levels in APOE2 mice
The main endogenous inhibitor of LPL, apoC-III, was
deleted from the genetic background of APOE2 mice by
crossbreeding with Apoc3-knockout mice. The effect of
Apoc3 deficiency on APOE2-associated hyperlipidemia was
investigated in APOE2 mice heterozygous or homozygous
deficient for the endogenous Apoc3 gene (Fig. 4). Sur-
prisingly, the plasma TG levels were not different between
APOE2, APOE2.Apoc31/2, and APOE2.Apoc32/2 mice
(Fig. 4A). The TC levels in APOE2 mice showed a tendency
toward a decrease by Apoc3 deficiency (Fig. 4B). No dif-
ferences in plasma lipid levels were found between male
and female mice (data not shown). The distribution of TG
and TC over the lipoprotein fractions was measured after
separation via FPLC (Fig. 5). No differences were observed
between APOE2, APOE2.Apoc31/2, and APOE2.Apoc32/2
mice in TG distribution (Fig. 5A), which is in full accor-
dance with the total plasma TG levels, However, the ten-
dency toward a decrease in TC levels by Apoc3 deficiency
is reflected by a decrease in cholesterol in the VLDL/LDL
fractions in the APOE2.Apoc31/2 and APOE2.Apoc32/2
mice (Fig. 5B).
To further analyze the effect of Apoc3 deficiency in
APOE2 mice on TG metabolism, mice were given an in-
tragastric olive oil load. The increase in plasma TG levels
was measured over a period of 3 h and the TG appearance
rate was determined. The increase in TG level over 3 h was
not different between APOE2 mice (0.9 6 1.6 mM; n 5 5),
APOE2.Apoc31/2 mice (1.1 6 0.4 mM; n 5 5), and
APOE2.Apoc32/2 mice (1.2 6 1.5 mM; n 5 4).
Effect of adenovirus-mediated expression of Apoa5 on
lipid levels in APOE2 mice
The activator of LPL, apoA-V, was expressed in APOE2
mice via a recombinant adenoviral vector (Fig. 6). In-
jection of a moderate dose of AdApoa5 (5 3 108 pfu)
reduced plasma TG by 81% (P , 0.05) and TC by 41%
(P , 0.05) compared with AdEmpty. Analysis of lipo-
Fig. 4. Plasma lipid levels of APOE2 mice deficient for Apoc3.
Fasted plasma samples were obtained from APOE2 mice (open
bars), APOE2.Apoc3+/2 mice (hatched bars), and APOE2.Apoc32/2
mice (closed bars). The samples were assayed for TG (A)
and cholesterol (B). Values are represented as means 6 SD for
n 5 5 mice per group.
Fig. 5. Lipoprotein profiles of APOE2 mice deficient for Apoc3.
Pooled plasma samples of APOE2, APOE2.Apoc31/2, and
APOE2.Apoc32/2 mice (n 5 5 per group) were subjected to FPLC,
and the elution fractions were assayed for TG (A) and choles-
terol (B).
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protein fractions separated by FPLC revealed that the
apoA-V-mediated reduction of plasma TG was associated
with a 4-fold reduction in VLDL-TG, whereas the TG level
in the intermediate density lipoprotein/LDL fraction
was affected to a minor degree. The reduction in plasma
TC level was associated with a 2-fold reduced VLDL-TC
level (Fig. 7).
DISCUSSION
In the current study, we have addressed the hypothesis
that alleviating the apoE2-mediated inhibition of lipolysis
can reduce the apoE2-associated hypertriglyceridemia.
Using the APOE2 mouse model, we first increased
circulating LPL activity directly via heparin injection.
This resulted in a reduction of the TG and TC levels in
APOE2 mice (Fig. 1). Likewise, injection of adenovirus
expressing LPL in APOE2 mice reduced the plasma TG
and TC levels (Fig. 2). The reduction in TG and TC was
confined mainly to the VLDL-sized fractions (data not
shown). These experiments demonstrated that apoE2-
containing particles are a suitable substrate for LPL.
Subsequently, LPL was stimulated indirectly via its op-
positely acting modulators apoC-III and apoA-V. Apoa5
overexpression did reduce the APOE2-associated hypertri-
glyceridemia in APOE2-knockin mice (Fig. 6). In contrast,
the APOE2-associated hypertriglyceridemia was not af-
fected by Apoc3 deficiency (Fig. 4). Our data indicate that
a direct increase of LPL activity by increasing circulat-
ing LPL levels reduces APOE2-associated hypertriglyc-
eridemia. The indirect stimulation of LPL activity via
Apoa5 overexpression but not Apoc3 deficiency ameliorates
the APOE2-associated hypertriglyceridemia. We conclude
that apoA-V is apparently dominant over apoC-III in the
improvement of APOE2-associated hypertriglyceridemia.
Moreover, apoA-V and apoC-III modulate LPL activity via
distinct mechanisms.
The effects of AdApoa5 injection on plasma lipid levels
of wild-type mice have been reported by us previously (8).
At the dose used in the current study (5 3 108 pfu/
mouse), AdApoa5 resulted in a significant decrease in TC
(68%) and TG (65%) in wild-type mice. In APOE2 mice,
AdApoa5 decreased TG more severely (81%) compared
with TC (41%), in agreement with a primary effect of
Fig. 6. Plasma lipid levels of APOE2 mice injected with AdApoa5.
APOE2 mice were injected consecutively with AdlacZ (5 3 108 pfu)
and AdApoa5 or AdEmpty (5 3 108 pfu). Before injection (open
bars) and at 4 days after injection (closed bars), fasted plasma was
collected from the individual mice and assayed for TG (A) and
cholesterol (B). Values are represented as means 6 SD for five mice
per group. * P , 0.05.
Fig. 7. Lipoprotein profiles of APOE2 mice injected with AdApoa5.
Pooled plasma samples of APOE2 mice injected with 5 3 108 pfu
AdMock or AdApoa5 (n5 5 per group) were subjected to FPLC, and
the elution fractions were assayed for TG (A) and cholesterol (B).
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apoA-V on lipolysis. The effect of apoC-III deficiency on
plasma lipid levels of wild-type mice revealed a more
dramatic effect on TG levels (74% reduction) compared
with TC levels (56% reduction) (15). This is also in agree-
ment with an increased activity of LPL in the absence of
apoC-III (11, 12, 15). Compared with wild-type mice, the
APOE2 mice displayed a combined hyperlipidemia,
characterized by increased levels of both TC and TG.
Because increasing circulating LPL levels decreased the
APOE2-associated hyperlipidemia, and specifically the
hypertriglyceridemia, the identical plasma TG levels of
APOE2, APOE2.Apoc31/2, and APOE2.Apoc32/2 mice are a
strong indication that apoC-III deficiency truly has very
little effect on the APOE2-associated hypertriglyceridemia.
Interestingly, the APOE2-associated hypercholesterolemia
seems reduced by Apoc3 deficiency (Fig. 4). It has been
reported that, besides inhibiting LPL, apoC-III can also
directly inhibit the hepatic uptake of apoE-containing
lipoproteins by the liver (25). Apparently, Apoc3 deficiency
in APOE2 mice does not affect LPL activity, as is evident
from unaltered plasma TG levels, but may enhance the
removal of cholesterol-enriched lipoprotein remnant par-
ticles, as is evident from reduced (V)LDL-cholesterol
levels (Fig. 5).
Addition of apoE to lipoproteins results in a decrease
in the LPL-mediated TG hydrolysis (26–28). This can at
least partially explain the hypertriglyceridemia that is
found in APOE2-associated familial dyslipidemia, which is
characterized by plasma accumulation of apoE-enriched
lipoproteins. It has been proposed that the inhibition
of LPL activity is caused by displacement of the LPL
coactivator apoC-II from the apoE2-rich lipoprotein par-
ticles (5). However, this is difficult to reconcile with the
observation that indirect stimulation of LPL activity via
apoA-V overexpression ameliorates the APOE2-associated
hyperlipidemia, especially because it has been dem-
onstrated that the LPL-activating effect of apoA-V is
dependent on the presence of apoC-II (8). Thus, other
mechanisms might underlie the inhibitory effect of apoE2
on LPL activity.
Under normal conditions, LPL-mediated TG hydrolysis
takes place mainly at the endothelial cell surface and thus
may be affected by the interaction between the TG-
containing particle and the cell surface where LPL is
localized. This interaction involves the association of TG-
rich particles and endothelial surface-bound heparan
sulfate proteoglycans (HSPGs) via apoE (29). It has been
shown that apoE2 is partly defective in the association with
HSPGs (30), and this could also explain part of the apoE2-
associated hypertriglyceridemia. In agreement with this
hypothesis, it has been found in vitro that VLDL obtained
from APOE2 homozygous familial dyslipidemia patients is
effectively lipolyzed by LPL in solution but is poorly lipo-
lyzed by HSPG-bound LPL (6). Thus, apoE2-containing
VLDL may be defective in the physical association with
the endothelial surfaces where LPL-mediated TG hydro-
lysis takes place in vivo. This would explain why both addi-
tional soluble LPL via adenovirus-mediated gene transfer
and increasing soluble LPL via heparin injection res-
cue the apoE2-associated hyperlipidemia. Intriguingly,
this explanation is also in agreement with the observation
that additional apoA-V rescues the apoE2-associated hy-
perlipidemia. It was found recently that the LPL-activating
effect of apoA-V involves enhanced binding to HSPGs
(10, 31). Thus, additional apoA-V on the TG-rich par-
ticle apparently overcomes the apoE2-mediated inhibi-
tion of HSPG binding. It is interesting that apoC-III
deficiency cannot overcome this binding defect, despite
the postulated inhibition of HSPG binding by apoC-III
(14, 32). However, the in vivo contribution of HSPGs to
the lipolysis of TG-rich lipoprotein particles still remains
to be determined.
Apart from a stimulatory effect on LPL, it may be
postulated that the decrease in plasma TG of APOE2
mice after the expression of apoA-V results from a
decrease in the VLDL-TG secretion rate by the liver. We
showed previously a 30% decreased VLDL-TG secre-
tion rate after adenovirus-mediated overexpression of
Apoa5 in wild-type C57BL/6 mice (8), whereas others
have found no effects of apoA-V on VLDL production in
either APOA5 transgenic mice (33) or Apoa52/2 mice (17).
Intriguingly, in the APOE2 mice, we observed no differ-
ences in the VLDL-TG secretion rate after injection of
AdApoa5 or AdEmpty (data not shown). At present, we
have no explanation for these apparent discrepancies
but cannot exclude the possibility that apoA-V has addi-
tional unrecognized functions.
Extrapolating our mouse model data to the human, it
seems likely that variation in apoA-V level will have a pro-
nounced effect on the expression of hypertriglyceridemia.
Surprisingly, we and others have found that in humans,
plasma TG and apoA-V levels are positively correlated (34–
36). This would appear to be a clear discrepancy between
mouse and human. However, it should be noted that the
human data are derived from correlation studies, whereas
the mouse data are derived from direct interventions in
plasma apoA-V levels. Without a complete understanding
of the role and metabolism of apoA-V, the apparent dis-
crepancy between circulating levels of apoA-V and hyper-
triglyceridemia remain to be resolved.
Polymorphisms in both the APOA5 and APOC3 genes
have been associated with hypertriglyceridemia (19, 37–
41). Because both genes are expressed in the same gene
cluster and have opposing effects on TG levels, it has been
hypothesized that APOA5 and APOC3 act synergistically
(7, 33). However, our current data clearly indicate that
apoA-V and apoC-III affect different steps in the conver-
sion of TG-rich lipoproteins to remnants.
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